Announcements Trials
Browse Landscape

Status

Completed 19Unknown 8Withdrawn 4Available 4Approved for marketing 3Active not recruiting 3Recruiting 2No longer available 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

CNS 4Endocrine 2

Conditions

Neuroblastoma 4Recurrence 2Pheochromocytoma 2Paraganglioma 1Neoplasms 1

Interventions

3-Iodobenzylguanidine 4tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1fluorodopa F 18 1fluorocholine 1epigallocatechin gallate 1ensartinib 1dodecyl maltoside 1carbon-11 methionine 1burosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Available × 3-Iodobenzylguanidine × Clear all
NCT01163383 2026-04-13

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Children's Hospital of Philadelphia

Available
CNS

Neuroblastoma

NCT01370330 2025-07-22

131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

University of California, San Francisco

Available
CNS

Neoplasms, Neuroblastoma, Recurrence

NCT03015844 2024-07-05

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Northwell Health

Available
CNSEndocrine

Neuroblastoma, Pheochromocytoma, Recurrence

NCT01590680 2023-02-28

Expanded Access Protocol Using 131I-MIBG

Jubilant DraxImage Inc.

Available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡